HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers

Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate

Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus es

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises t

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncolog

Investors need to pay close attention to AGEN stock based on the movements in the options market lat

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in i

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer stud

Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average

U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and

ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech d

HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f

Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-onco

Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended it

Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase

US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on e

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline resul

VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has enter

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% thre

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launc

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste

Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated

Published prospective cohort showed durable responses and manageable safety in patients with HCC fol

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal ca

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximate

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has trig

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinic

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and c

Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid n